Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v17-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated (Changed) | Updated to: 2022-03-22 | Was: 2021-11-18 |
| Drug Identification Number | 02240352 | 02240352 |
| Brand name | INTEGRILIN | INTEGRILIN |
| Common or Proper name | Eptifibatide Injection | Eptifibatide Injection |
| Company Name | MERCK CANADA INC | MERCK CANADA INC |
| Ingredients | EPTIFIBATIDE | EPTIFIBATIDE |
| Strength(s) | 2MG | 2MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1 | 1 |
| Additional packaging sizes | ||
| ATC code | B01AC | B01AC |
| ATC description | ANTITHROMBOTIC AGENTS | ANTITHROMBOTIC AGENTS |
| Reason for shortage (Changed) | Updated to: Requirements related to complying with good manufacturing practices. | Was: Other (Please describe in comments) |
| Anticipated start date (Changed) | Updated to: 2021-11-26 | Was: 2021-11-22 |
| Actual start date (Changed) | Updated to: 2021-11-24 | Was: |
| Estimated end date (Changed) | Updated to: 2022-03-29 | Was: 2021-12-29 |
| Actual end date (Changed) | Updated to: 2022-03-22 | Was: |
| Shortage status (Changed) | Updated to: Actual shortage | Was: Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments (Changed) | Updated to: | Was: tbc |
| Health Canada comments |